Bio-Light Life Sciences
We are an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome, or DES, and age-related macular degeneration, or AMD. Our current products and product candidates are designed to address a number of significant unmet medical needs of large and growing patient populations related to these ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering better diagnosis and optimizing delivery of medications.
Leading key investors, holding about 60% of BioLight’s issued and outstanding shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India’s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel and Rock One A Hong Kong investment based company.
BioLight is a public traded company on the Tel-Aviv Stock Exchange (BOLT).
An Ophthalmic Home Diagnostic Services company, Notal Vision extends retina disease management from the clinic to the home to improve vision outcomes, reduce patient burden, and address healthcare costs. With a proven approach to the home testing experience, patient-operated devices, and real-time AI-enabled data interpretation, we are advancing eyecare through precision medicine. It is this unique assembly of core competencies that enables us to deliver personalized eyecare to patients. Retinal diseases that present with acute onset, unpredictable activity, and varying drug response pose challenges to healthcare and create addressable unmet needs. Home Diagnostic Services support the promise of enabling patients to retain functional vision throughout their years-long disease journey.
Ora is the world’s leading full-service ophthalmic CRO and product development firm with offices in the United States, the United Kingdom, Australia and Japan. Over the past 40 years, we have proudly helped our clients earn more than 45 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world’s most extensive and experienced team of ophthalmic experts and R&D professionals to maximize the value of new product initiatives.